Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

BACKGROUND: Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse cardiac events (MACE) in patients with cardiovascular disease (CVD) by 44% and in diabetic CVD patients by 57% on top of statins. A ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsujikawa, Laura M., Fu, Li, Das, Shovon, Halliday, Christopher, Rakai, Brooke D., Stotz, Stephanie C., Sarsons, Christopher D., Gilham, Dean, Daze, Emily, Wasiak, Sylwia, Studer, Deborah, Rinker, Kristina D., Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626370/
https://www.ncbi.nlm.nih.gov/pubmed/31300040
http://dx.doi.org/10.1186/s13148-019-0696-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626370/
https://www.ncbi.nlm.nih.gov/pubmed/31300040
http://dx.doi.org/10.1186/s13148-019-0696-z

Ejemplares similares